Premium
Treatment of Acute Myeloid Leukaemia in Children
Author(s) -
Paton C. M.,
Ekert H.,
Waters K. D.,
Matthews R. N.,
Toogood I. R. G.
Publication year - 1982
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1982.tb02446.x
Subject(s) - medicine , myeloid leukaemia , cyclophosphamide , daunorubicin , myeloid , complete remission , gastroenterology , cytarabine , surgery , leukemia , chemotherapy , pediatrics
Treatment of acute myeloid leukaemia in children . C. M. Paton, H. Ekert, K. D. Waters, R. N. Matthews and I. R. G. Toogood, Aust. N.Z. J. Med., 1982, 12, pp. 143–146. Complete remission was achieved in 11 of 22 children with acute myeloid leukaemia using at least two courses of a 24 hour infusion of cytosine arabinoside (Ara–C) 10 mg/kg, followed by push injections of daunorubicin (DNR) 45 mglm 2 , and adriamycin (ADR) 45 mglm 2 . Consolidation therapy consisted of three courses of Ara–C and 6–thioguanine (Tg) and one course of cyclophosphamide (CPA) and ADR. Central nervous system prophylaxis with intrathecal Ara–C was given in all patients and cranial irradiation in five. Maintenance therapy consisted of 5 day courses of Ara–C and Tg given 4 weekly with immunotherapy (BCG vaccine and subcutaneous leukaemic cells) between courses. Median length of first complete remission was 99+ weeks, and median survival of all patients was 44 weeks. Median survival of remitters was 195+ weeks and non–remitters, 28 weeks. Two patients developed central nervous system disease, one at presentation and the other 46 weeks from presentation. Five patients have ceased therapy and remain in remission from 32 to 142 weeks after ceasing treatment.